These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 22397764

  • 1. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 2. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 3. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ.
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [Abstract] [Full Text] [Related]

  • 4. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 5. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Apr 15; 20(8):2029-34. PubMed ID: 24573551
    [Abstract] [Full Text] [Related]

  • 6. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.
    Lung Cancer; 2015 Feb 15; 87(2):89-95. PubMed ID: 25576294
    [Abstract] [Full Text] [Related]

  • 7. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH.
    Expert Rev Anticancer Ther; 2012 Feb 15; 12(2):151-62. PubMed ID: 22316363
    [Abstract] [Full Text] [Related]

  • 8. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA, Velez M, Raez LE, Santos ES.
    Lung Cancer; 2014 May 15; 84(2):110-5. PubMed ID: 24598368
    [Abstract] [Full Text] [Related]

  • 9. Treatment and detection of ALK-rearranged NSCLC.
    Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.
    Lung Cancer; 2013 Aug 15; 81(2):145-54. PubMed ID: 23769207
    [Abstract] [Full Text] [Related]

  • 10. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM, Rudin CM.
    Expert Opin Pharmacother; 2012 Jun 15; 13(8):1195-201. PubMed ID: 22594847
    [Abstract] [Full Text] [Related]

  • 11. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R.
    Oncologist; 2014 Oct 15; 19(10):e5-11. PubMed ID: 25170012
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 15; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 13. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A, Wood K, Salgia R.
    Expert Opin Drug Saf; 2015 Mar 15; 14(3):485-93. PubMed ID: 25659177
    [Abstract] [Full Text] [Related]

  • 14. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul 15; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 15. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI, Gautschi O.
    Clin Lung Cancer; 2013 Sep 15; 14(5):473-80. PubMed ID: 23790969
    [Abstract] [Full Text] [Related]

  • 16. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.
    Expert Opin Pharmacother; 2013 Apr 15; 14(5):597-608. PubMed ID: 23472711
    [Abstract] [Full Text] [Related]

  • 17. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L, Solomon B.
    Drugs; 2015 Jul 15; 75(10):1059-70. PubMed ID: 26076736
    [Abstract] [Full Text] [Related]

  • 18. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Curr Clin Pharmacol; 2016 Jul 15; 11(2):77-87. PubMed ID: 27138017
    [Abstract] [Full Text] [Related]

  • 19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 15; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 20. New targets in advanced NSCLC: EML4-ALK.
    Crystal AS, Shaw AT.
    Clin Adv Hematol Oncol; 2011 Mar 15; 9(3):207-14. PubMed ID: 21475126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.